FindTrial
Sign In

Rabbit ATG

DRUG12 trials

Sponsors

M.D. Anderson Cancer Center, Sherif S. Farag, Weill Medical College of Cornell University, Children's Hospital Medical Center, Cincinnati, Novartis Pharmaceuticals

Conditions

Acquired Amegakaryocytic ThrombocytopeniaAcquired Pure Red Cell AplasiaAcute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaAcute Myelogenous LeukemiaAcute Myelogenous Leukemia (AML)Acute Myeloid LeukemiaAplastic Anemia

Phase 1

Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
CompletedNCT02916979
Dartmouth-Hitchcock Medical CenterLeukemia, Lymphoid, Leukemia, Myeloid, Lymphoma, Malignant +4
Start: 2016-09-06End: 2022-02-11Updated: 2023-10-18

Phase 2

Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
CompletedNCT00038857
M.D. Anderson Cancer CenterLeukemia, Lymphoma
Start: 2001-09-30End: 2009-06-30Updated: 2012-08-10
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
TerminatedNCT00593554
Sherif S. FaragAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia +1
Start: 2007-08-07End: 2017-07-28Updated: 2018-04-10
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
TerminatedNCT01745913
Weill Medical College of Cornell UniversityAcute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma +2
Start: 2012-10-26End: 2015-04-29Updated: 2018-07-11
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
RecruitingNCT02143830
Children's Hospital Medical Center, CincinnatiAcute Myelogenous Leukemia (AML), Fanconi Anemia, Myelodysplastic Syndrome (MDS) +1
Start: 2014-04-30End: 2028-12-31Target: 70Updated: 2025-11-12
Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
CompletedNCT02404025
Novartis PharmaceuticalsAplastic Anemia
Start: 2015-05-12End: 2017-09-06Updated: 2019-07-26
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
RecruitingNCT02828592
Northside Hospital, Inc.Severe Aplastic Anemia
Start: 2016-09-09End: 2027-08-31Target: 20Updated: 2025-10-30
Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
NCT05214066
Chinese PLA General HospitalaGVHD, cGVHD
Start: 2019-02-01End: 2022-08-01Target: 60Updated: 2022-02-22
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
WithdrawnNCT05293509
M.D. Anderson Cancer CenterStem Cell Transplantation
Start: 2022-03-02End: 2023-09-18Updated: 2023-09-21
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RecruitingNCT05736419
Memorial Sloan Kettering Cancer CenterSickle Cell Disease, Thalassemia, Thalassemia, Beta
Start: 2023-02-09End: 2027-02-09Target: 24Updated: 2026-03-05
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
RecruitingNCT06412497
Masonic Cancer Center, University of MinnesotaAcquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria +1
Start: 2024-06-05End: 2036-05-01Target: 60Updated: 2025-06-19

Unknown Phase

Pediatric Induction Therapy in Kidney Transplantation
CompletedNCT06087003
Gang ChenKidney Transplant Rejection, Pediatric Kidney Disease
Start: 2013-03-03End: 2023-09-30Updated: 2023-10-17